This is a translation of a Spanish language announcement filed with the CNMV. In case of discrepancies, the Spanish version will prevail.

RELEVANT EVENT

In compliance with article 82 of the Financial Markets Legislation (Ley del Mercado de Valores), GRIFOLS, S.A. (“Grifols”) informs of the filing with the Securities Exchange Commission of the F-4 (Form F-4, Registration Statement under the Securities Act of 1933), relating to the acquisition of 100% of the share capital of Talecris Biotherapeutics Holding Corporation. The F-4 can be accessed on the web site of the Securities Exchange Commission through the link bellow:

http://sec.gov/Archives/edgar/data/1438569/000095012311003042/y85911b3e424b3.htm

Barcelona, January 17 2011

Raimon Grifols Roura
Secretary of the Board of Directors